Survodutide vs Semaglutide
A glucagon dual agonist vs the approved GLP-1 standard
Semaglutide (Ozempic/Wegovy) is the approved GLP-1 you can use today; survodutide (Boehringer Ingelheim) adds glucagon agonism for extra energy expenditure and standout liver-disease data. Here is how the investigational dual compares with the proven single-agonist standard.
One receptor vs two
Semaglutide acts on the GLP-1 receptor alone — suppressing appetite and slowing gastric emptying — and is the most widely used drug in this class, with about 15% mean weight loss in STEP-1 and a deep real-world track record. Survodutide adds a second target, the glucagon receptor, which raises energy expenditure and drives liver-fat oxidation on top of GLP-1’s appetite effects.
In a Phase 2 obesity trial, survodutide produced roughly 19% mean weight loss at 46 weeks, and its Phase 2 MASH trial showed meaningful improvement in liver inflammation and fibrosis. Semaglutide also has positive liver-disease data and the major advantage of being approved and available.
As always, the percentages come from separate trials with different designs, so they are directional rather than a precise head-to-head ranking.
Survodutide vs Semaglutide at a glance
- ⚡Mechanism: GLP-1 + glucagon dual agonist
- ⚡Phase 2 obesity: about 19% mean weight loss at 46 weeks
- ⚡Standout Phase 2 data in MASH (liver inflammation + fibrosis)
- ⚡Glucagon adds energy expenditure and liver-fat reduction
- ⚡Status: investigational — Phase 3 ongoing, not FDA approved
- ✓Mechanism: GLP-1 receptor agonist (single target)
- ✓STEP-1: about 15% mean weight loss at 68 weeks
- ✓Large real-world track record + positive liver-disease data
- ✓Once-weekly pen (and an oral tablet, Rybelsus)
- ✓FDA approved for obesity and type 2 diabetes — available now
Which fits your goals?
If you want a proven, approved option you can start now — with years of real-world data and both injectable and oral forms — semaglutide is the practical choice. Its weight loss is more modest than the newer duals and triples, but its safety profile is the best characterized in the class.
Survodutide is the one to watch if you are specifically interested in the glucagon mechanism for deeper weight loss or for liver disease. It is investigational, so it cannot be prescribed yet, and its profile may shift as Phase 3 results report.
Track now, compare later
With no head-to-head trial, your own data is the most reliable input for a future decision. Logging semaglutide outcomes in Shotlee — weight trend, appetite, side effects, and labs — builds an objective baseline, so if survodutide becomes available you can compare results with precision.
Use this comparison as a framework and confirm the details with your healthcare provider, especially if liver health is part of your decision.
Survodutide vs Semaglutide: Frequently Asked Questions
There is no head-to-head trial. Survodutide reported deeper Phase 2 weight loss (about 19%) and stronger liver/MASH signals thanks to its glucagon mechanism, while semaglutide is approved, widely used, and has about 15% weight loss in STEP-1 plus positive liver data. Survodutide is still investigational.
Survodutide is a GLP-1/glucagon dual agonist (glucagon adds energy expenditure and liver-fat reduction); semaglutide is a single GLP-1 receptor agonist. Semaglutide is FDA approved (Ozempic/Wegovy/Rybelsus); survodutide is in Phase 3.
Both have liver-disease data. Survodutide’s glucagon mechanism specifically targets liver fat and showed meaningful MASH improvement in Phase 2, but it is investigational. Semaglutide also has positive MASH data and is available now. A hepatologist should guide treatment decisions.
Survodutide reported about 19% at 46 weeks (Phase 2); semaglutide reported about 15% at 68 weeks (STEP-1). These are separate trials and not directly comparable.
Yes. Shotlee logs doses, weight, side effects, and labs for your current protocol, free — ready to compare if you change medications.
Track Your Protocol in Shotlee
Free dose logging, weight trends, lab snapshots, and side effect tracking.
